Moleculin Biotech, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sara Nik from H.C. Wainwright reiterated a Buy rating on the stock and has a $4.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sara Nik has given her Buy rating due to a combination of factors that highlight Moleculin Biotech’s promising developments in their drug pipeline. One key factor is the initiation of an investigator-sponsored trial (IST) for annamycin, aimed at treating pancreatic cancer. This trial, set to begin in 2026, is based on compelling preclinical data that showed significant activity of annamycin against pancreatic cancer and liver metastases. The expansion into this new tumor indication is seen as a positive step that could enhance the potential market opportunity for annamycin.
Additionally, the ongoing Phase 3 MIRACLE study for annamycin in relapsed or refractory acute myeloid leukemia (r/r AML) is gaining momentum, with increased patient recruitment and site activation globally. Moleculin’s strategic expansion into new regions and the addition of more study sites demonstrate the company’s commitment to advancing this pivotal study. The potential for robust efficacy and safety data from this trial could pave the way for a rolling New Drug Application process, further supporting the Buy rating given by Sara Nik.
Nik covers the Healthcare sector, focusing on stocks such as Cidara Therapeutics, Moleculin Biotech, and Curis. According to TipRanks, Nik has an average return of 34.2% and a 41.67% success rate on recommended stocks.